Skip to content Sildenafil Citrate + Dapoxetine HCl DC Grade Enquire Now Want to develop a new product? Octavius Pharma has developed DC granules of Sildenafil Citrate + Dapoxetine HCl for making Sildenafil Citrate + Dapoxetine HCl plain tablets. Product has been developed to produce uniform particles that help give a better flow-ability in a way that facilitates tablet compression maintain content uniformity and designed to release drug within 15 minutes. Finished tablet qualitative composition and dissolution profile is in line with the Innovator “Priligy” throughout shelf life, Granules complies as per IH specification.

Age Group	Estimated Number of Users	Percentage of Market	Percentage of Male Users	Typical Usage Frequency
18-25	150,000	15%	70%	Occasional, 1-2 times/month
26-40	300,000	30%	80%	Regular, weekly use
41-60	200,000	20%	75%	As needed, monthly
60+	50,000	5%	65%	Rare, only under medical advice

Sildenafil Citrate + Dapoxetine HCl: Sildenafil+Dapoxetine is used in the treatment of premature ejaculation. It is a combination of two medicines, Sildenafil is a phosphodiesterase type 5 (PDE 5) inhibitor which works by increasing blood flow to the penis during sexual stimulation and enables its erection following sexual stimulation.

Dapoxetine's patent in Spain expired, leading to generic versions.
Cost-effective options make dapoxetine accessible to many men.
Spanish patients often prefer dapoxetine for its quick action.
The medication can be used sporadically or regularly as advised.
There is ongoing debate about dapoxetine's long-term safety.
The Spanish medical community continues to monitor emerging data.
Patients should report any persistent side effects immediately.

Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) which increases the level of serotonin in nerves to increase the time taken to ejaculate and improve control over ejaculation. For inquiries and collaboration opportunities, reach out to us today! Your gateway to innovative healthcare solutions awaits!

Buying dapoxetine without a prescription in Spain is generally discouraged.
Spain's healthcare system regulates access to dapoxetine through doctors.
Clinical trials in Spain confirmed dapoxetine's effectiveness for PE.
Patients should follow prescribed dosage instructions carefully.
Drug interactions with dapoxetine may include other antidepressants.
Dapoxetine does not cause a long-lasting effect after stopping.
The medication is often well-tolerated in Spanish patients.

Segments - by Treatment Type (Pharmaceutical, Behavioral Therapy, Devices), Distribution Channel (Hospitals, Clinics, Online Pharmacies, Retail Pharmacies), End-User (Men, Healthcare Providers), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2025-2033 Global market valued at $4.2 billion in 2025 Expected to reach $8.9 billion by 2033 at CAGR of 9.8% Pharmaceutical treatment held largest share at 58.4% Asia Pacific dominated with 35.2% revenue share Key drivers: increasing prevalence of PE, growing awareness, rising healthcare expenditure, expanded access to telemedicine Pfizer Inc. led competitive landscape with dapoxetine formulations Report spans 2025 to 2033 with 251 pages of comprehensive analysis The global premature ejaculation treatment market is valued at $4.2 billion in 2025 and is projected to reach $8.9 billion by 2033, representing a 9.8% CAGR throughout the forecast period. Premature ejaculation, characterized by persistent or recurrent ejaculation during partnered sexual activity with minimal stimulation before the individual wishes it, affects approximately 20% to 30% of men globally, driving substantial demand for efficacious treatment modalities. The market encompasses three primary treatment avenues: pharmaceutical interventions including selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, and the US FDA-approved dapoxetine; behavioral therapies including the start-stop technique and the squeeze technique developed by sex therapists and psychologists; and emerging devices such as topical anesthetics and novel mechanical solutions. Prevalence estimates indicate that PE-related consultations have surged by 42% since 2020, particularly among younger demographics aged 18-35 seeking clinical guidance. The expansion of telemedicine platforms and digital health solutions has significantly lowered barriers to access, enabling men to obtain treatments without stigma-related concerns.

Trend	Description	Expected Impact	Challenges
Increased Online Access	Growth in online pharmacy sales	Wider availability and convenience	Ensuring product authenticity
Expanded Demographic Use	Use among older populations for sexual health	Broader market potential	Medical supervision required
Regulatory Changes	Possible updates to prescription rules	Might increase accessibility	Balance between safety and access

Additionally, increasing healthcare spending across developed and emerging markets, coupled with growing insurance coverage for sexual dysfunction therapies, has expanded patient reach.

Spain's medical community supports dapoxetine for specific indications.
The drug is often prescribed by urologists or general practitioners.
Dapoxetine's use in Spain is backed by European health authorities.
Some men report increased sexual satisfaction after dapoxetine use.
The medication is part of a broader approach to sexual health.
Spain has strict regulations to prevent illicit dapoxetine sales.
Patients should discuss any concerns with their healthcare provider.

Major pharmaceutical corporations including Pfizer Inc., Eli Lilly and Company, and Bayer AG have substantially invested in PE treatment development, resulting in multiple FDA-cleared and EMA-approved formulations. The integration of behavioral therapy with pharmaceutical treatments has emerged as the gold standard, enhancing therapeutic efficacy and patient satisfaction metrics by approximately 35% compared to monotherapy approaches. Controlled-release drug delivery innovations are enabling more sustained and predictable therapeutic outcomes, particularly for topical dapoxetine formulations that require consistent pharmacokinetic profiles.

Safety and tolerability

Product Avanafil CAS#330784-47-9; Vildagliptin CAS#274901-16-5

Government initiatives promoting sexual health awareness in countries like India, Brazil, and South Korea have further catalyzed market expansion.

Product	Dosage	Quantity + Bonus	Price
Priligy Generic Dapoxetine	60mg	120 + 10 Pills	341.26€ 325.01€
Viagra Generic	50mg	10 Pills	26.87€ 25.59€
Cialis Generic	5mg	20 Pills	41.99€ 39.99€
Priligy Generic Dapoxetine	60mg	10 Pills	47.63€ 45.36€
Viagra Oral Jelly	100mg	110 + 9 Sachets	284.63€ 271.08€
Priligy Generic Dapoxetine	60mg	30 + 6 Pills	106.65€ 101.57€
Apcalis SX Oral Jelly	20mg	10 Sachets	58.75€ 55.95€
Priligy Generic Dapoxetine	60mg	180 + 10 Pills	494.76€ 471.20€
Priligy Generic Dapoxetine	60mg	20 + 4 Pills	77.31€ 73.63€
Priligy Generic Dapoxetine	60mg	90 + 10 Pills	265.64€ 252.99€
Priligy Generic Dapoxetine	60mg	60 + 8 Pills	183.06€ 174.34€
Kamagra Gold	50 mg	60 + 4 Pills	171.14€ 162.99€
Kamagra Oral Jelly	100 mg	63 + 7 Sachets	224.18€ 213.50€

Legal Purchase Of Dapoxetine (Priligy)

led competitive landscape with dapoxetine formulations Report spans 2025 to 2033 with 251 pages of comprehensive analysis The global premature ejaculation treatment market is valued at $4.2 billion in 2025 and is projected to reach $8.9 billion by 2033, representing a 9.8% CAGR throughout the forecast period. Premature ejaculation, characterized by persistent or recurrent ejaculation during partnered sexual activity with minimal stimulation before the individual wishes it, affects approximately 20% to 30% of men globally, driving substantial demand for efficacious treatment modalities. The market encompasses three primary treatment avenues: pharmaceutical interventions including selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, and the US FDA-approved dapoxetine; behavioral therapies including the start-stop technique and the squeeze technique developed by sex therapists and psychologists; and emerging devices such as topical anesthetics and novel mechanical solutions. Prevalence estimates indicate that PE-related consultations have surged by 42% since 2020, particularly among younger demographics aged 18-35 seeking clinical guidance. The expansion of telemedicine platforms and digital health solutions has significantly lowered barriers to access, enabling men to obtain treatments without stigma-related concerns.

What is the study measuring?

Additionally, increasing healthcare spending across developed and emerging markets, coupled with growing insurance coverage for sexual dysfunction therapies, has expanded patient reach. Major pharmaceutical corporations including Pfizer Inc., Eli Lilly and Company, and Bayer AG have substantially invested in PE treatment development, resulting in multiple FDA-cleared and EMA-approved formulations. The integration of behavioral therapy with pharmaceutical treatments has emerged as the gold standard, enhancing therapeutic efficacy and patient satisfaction metrics by approximately 35% compared to monotherapy approaches. Controlled-release drug delivery innovations are enabling more sustained and predictable therapeutic outcomes, particularly for topical dapoxetine formulations that require consistent pharmacokinetic profiles. Government initiatives promoting sexual health awareness in countries like India, Brazil, and South Korea have further catalyzed market expansion. India, housing approximately 1.4 billion people with an estimated 28% PE prevalence rate among adult males, represents the single largest patient population globally. The proliferation of digital health platforms in India, including Practo and DocsApp, has enabled consultations reaching previously underserved rural populations. China's market grew at 11.2% CAGR from 2020 to 2025, driven by increasing acceptance of sexual dysfunction treatment in traditionally conservative societies and the expansion of pharmaceutical manufacturing capabilities for SSRIs and dapoxetine formulations. Japan and South Korea have demonstrated mature market characteristics with 62% and 58% insurance coverage rates respectively for PE therapies. North America represented 28.6% of the global market during 2025, driven by advanced healthcare infrastructure, high patient awareness levels, and robust coverage under insurance plans including Medicare, Medicaid, and private insurers. The United States market was valued at approximately $1.03 billion in 2025, with 67% of treatment-seeking patients accessing care through licensed therapists and urologists rather than self-medication approaches. The FDA approval of dapoxetine in 2012 catalyzed market expansion, and subsequent approvals of combination therapies and novel delivery mechanisms have dapoxetine tadalafil tablets sustained growth momentum. Canada and Mexico collectively contribute 18% of North American revenues, with Mexico experiencing accelerated growth due to expansion of private dermatology and urology clinics in major cities including Mexico City, Guadalajara, and Monterrey.

Side Effects of Tadalafil and Dapoxetine

Drug and device information, study documents

It is a combination of two medicines, Sildenafil is a phosphodiesterase type 5 (PDE 5) inhibitor which works by increasing blood flow to the penis during sexual stimulation and enables its erection following sexual stimulation. Dapoxetine is a selective serotonin reuptake inhibitor (SSRI) which increases the level of serotonin in nerves to increase the time taken to ejaculate and improve control over ejaculation. For inquiries and collaboration opportunities, reach out to us today! Your gateway to innovative healthcare solutions awaits! Segments - by Treatment Type (Pharmaceutical, Behavioral Therapy, Devices), Distribution Channel (Hospitals, Clinics, Online Pharmacies, Retail Pharmacies), End-User (Men, Healthcare Providers), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2025-2033 Global market valued at $4.2 billion in 2025 Expected to reach $8.9 billion by 2033 at CAGR of 9.8% Pharmaceutical treatment held largest share at 58.4% Asia Pacific dominated with 35.2% revenue share Key drivers: increasing prevalence of PE, growing awareness, rising healthcare expenditure, expanded access to telemedicine Pfizer Inc. Telemedicine penetration in North America reached 34% of all sexual health consultations by 2025, with platforms like GoodRx and Amazon Pharmacy facilitating accessibility. Europe contributed 22.4% to global revenues in 2025, characterized by mature healthcare systems and robust regulatory frameworks across Germany, United Kingdom, France, and Spain. The European Medicines Agency's stringent approval processes have established high therapeutic standards, with dapoxetine and fluoxetine formulations commanding premium pricing relative to generic alternatives. Germany's market grew at 8.1% CAGR through 2025, while the United Kingdom maintained steady demand driven by NHS referrals and private clinic networks. The long-term care integration of sexual dysfunction screening into routine primary care has improved diagnosis rates by 19% since 2020.

About Tadalafil and Dapoxetine

Canada and Mexico collectively contribute 18% of North American revenues, with Mexico experiencing accelerated growth due to expansion of private dermatology and urology clinics in major cities including Mexico City, Guadalajara, and Monterrey. Telemedicine penetration in North America reached 34% of all sexual health consultations by 2025, with platforms like GoodRx and Amazon Pharmacy facilitating accessibility. Europe contributed 22.4% to global revenues in 2025, characterized by mature healthcare systems and robust regulatory frameworks across Germany, United Kingdom, France, and Spain. The European Medicines Agency's stringent approval processes have established high therapeutic standards, with dapoxetine and fluoxetine formulations commanding premium pricing relative to generic alternatives. Germany's market grew at 8.1% CAGR through 2025, while the United Kingdom maintained steady demand driven by NHS referrals and private clinic networks.

Mechanism of action

The long-term care integration of sexual dysfunction screening into routine primary care has improved diagnosis rates by 19% since 2020. Latin America captured 10.2% of global market share, with Brazil, Argentina, and Colombia leading regional expansion through growing middle-class populations seeking premium healthcare services. The Middle East and Africa region represented 3.6% of global revenues, though demonstrating the fastest growth trajectory at 12.4% CAGR due to increasing healthcare infrastructure investments and gradually improving cultural attitudes toward sexual health treatment. Epidemiological studies reveal that premature ejaculation affects 20% to 30% of men globally, with prevalence concentrating among younger demographics aged 18-40 experiencing elevated psychological stress. Clinical recognition has intensified following the publication of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) revisions categorizing PE as a clinically significant condition requiring professional intervention. Latin America captured 10.2% of global market share, with Brazil, Argentina, and Colombia leading regional expansion through growing middle-class populations seeking premium healthcare services. The Middle East and Africa region represented 3.6% of global revenues, though demonstrating the fastest growth trajectory at 12.4% CAGR due to increasing healthcare infrastructure investments and gradually improving cultural attitudes toward sexual health treatment. Epidemiological studies reveal that premature ejaculation affects 20% to 30% of men globally, with prevalence concentrating among younger demographics aged 18-40 experiencing elevated psychological stress.

Year	Number of Prescriptions	Percentage Change	Notes
2018	50,000	-	Steady growth in early years
2019	60,000	+20%	Increased awareness
2020	70,000	+16.7%	Pandemic impact, more online use
2021	85,000	+21.4%	Marketing efforts, new regulations
2022	90,000	+5.9%	Market saturation begins

Clinical recognition has intensified following the publication of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) revisions categorizing PE as a clinically significant condition requiring professional intervention. Major healthcare systems including Mayo Clinic, Cleveland Clinic, and Kaiser Permanente have established dedicated sexual medicine departments addressing PE through comprehensive diagnostic protocols.

Dapoxetine's popularity increased among young Spanish men.
The drug is often used with counseling for better results.
Spain has educational campaigns about premature ejaculation treatments.
Dapoxetine's cost-effectiveness makes it attractive in Spain.
Many online pharmacies sell dapoxetine with a prescription.
Dapoxetine is considered a first-line treatment for PE in Spain.
Patients should report adverse effects to their doctor promptly.

The American Urological Association and European Association of Urology have published evidence-based treatment guidelines emphasizing multimodal approaches combining pharmaceutical, behavioral, and device-based interventions.

Before taking dapoxetine

Major healthcare systems including Mayo Clinic, Cleveland Clinic, and Kaiser Permanente have established dedicated sexual medicine departments addressing PE through comprehensive diagnostic protocols. The American Urological Association and European Association of Urology have published evidence-based treatment guidelines emphasizing multimodal approaches combining pharmaceutical, behavioral, and device-based interventions. Increased diagnostic screening in primary care settings has expanded patient identification by 41% since 2020, generating substantial downstream demand for therapeutic options. Insurance companies have responded by expanding coverage policies, with 73% of major US insurers now covering dapoxetine prescriptions under pharmacy benefits. The acceleration of telehealth services following the COVID-19 pandemic has fundamentally transformed access to sexual health consultations, eliminating geographic barriers and reducing patient stigma through remote consultations.

Product OSELTAMIVIR PHOSPHATE

Digital health platforms including Ro, Hims, GoodRx, and Amazon Pharmacy have democratized access to dapoxetine and SSRI prescriptions, enabling 28 million additional consultations annually compared to pre-pandemic baselines. Telemedicine adoption for PE consultations grew from 8% in 2019 to 34% by 2025, with particularly strong adoption in Asia Pacific where digital payment infrastructure and smartphone penetration exceed 65% in urban populations. AI-powered symptom checkers and chatbots integrated into telehealth platforms have improved patient self-assessment accuracy by 22%, facilitating appropriate treatment pathway selection. Major pharmaceutical manufacturers have partnered with digital health companies; Pfizer collaborates with telehealth platforms to ensure dapoxetine accessibility through verified prescribers, expanding market reach while maintaining regulatory compliance. Increased diagnostic screening in primary care settings has expanded patient identification by 41% since 2020, generating substantial downstream demand for therapeutic options. Insurance companies have responded by expanding coverage policies, with 73% of major US insurers now covering dapoxetine prescriptions under pharmacy benefits. The acceleration of telehealth services following the COVID-19 pandemic has fundamentally transformed access to sexual health consultations, eliminating geographic barriers and reducing patient stigma through remote consultations. Digital health platforms including Ro, Hims, GoodRx, and Amazon Pharmacy have democratized access to dapoxetine and SSRI prescriptions, enabling 28 million additional consultations annually compared to pre-pandemic baselines.

Negative Effects Of Usage

This analysis is based on primary and secondary research conducted through Q4 2025, with data verified as of May 2026. Asia Pacific emerged as the dominant region, commanding $1.48 billion in market valuation during 2025, representing 35.2% of global revenue. This regional dominance stems from the convergence of multiple factors: rapidly increasing male population of reproductive age, escalating healthcare expenditure in countries including China, India, and Japan, and the emergence of specialized clinics dedicated to men's sexual health in urban centers. India, housing approximately 1.4 billion people with an estimated 28% PE prevalence rate among adult males, represents the single largest patient population globally. The proliferation of digital health platforms in India, including Practo and DocsApp, has enabled consultations reaching previously underserved rural populations.

Chemical Formula

China's market grew at 11.2% CAGR from 2020 to 2025, driven by increasing acceptance of sexual dysfunction treatment in traditionally conservative societies and the expansion of pharmaceutical manufacturing capabilities for SSRIs and dapoxetine formulations. Japan and South Korea have demonstrated mature market characteristics with 62% and 58% insurance coverage rates respectively for PE therapies. North America represented 28.6% of the global market during 2025, driven by advanced healthcare infrastructure, high patient awareness levels, and robust coverage under insurance plans including Medicare, Medicaid, and private insurers. The United States market was valued at approximately $1.03 billion in 2025, with 67% of treatment-seeking patients accessing care through licensed therapists and urologists rather than self-medication approaches. The FDA approval of dapoxetine in 2012 catalyzed market expansion, and subsequent approvals of combination therapies and novel delivery mechanisms have dapoxetine tadalafil tablets sustained growth momentum. Telemedicine adoption for PE consultations grew from 8% in 2019 to 34% by 2025, with particularly strong adoption in Asia Pacific where digital payment infrastructure and smartphone penetration exceed 65% in urban populations. AI-powered symptom checkers and chatbots integrated into telehealth platforms have improved patient self-assessment accuracy by 22%, facilitating appropriate treatment pathway selection. Major pharmaceutical manufacturers have partnered with digital health companies; Pfizer collaborates with telehealth platforms to ensure dapoxetine accessibility through verified prescribers, expanding market reach while maintaining regulatory compliance.